INSP
Inspire Medical Systems, Inc.
$69.10
-2.39
(-3.34%)
Mkt Cap
2.02B
Volume
311,864
52W Range
38.91-147.03
Sector
Healthcare
Beta
0.73
EPS (TTM)
4.66 USD
P/E Ratio
15.02
Revenue (TTM)
898.74M USD
Rev Growth (5Y)
+51.2%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$9.73
Overvalued
strong signal
619.1% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 911.98M | 802.80M | 624.80M | 407.86M | 233.39M | 115.38M | 82.05M | 50.59M | 28.57M | 16.43M | 8.01M |
| Net Income | 145.42M | 53.51M | (21.15M) | (44.88M) | (42.04M) | (57.20M) | (33.24M) | (21.83M) | (17.51M) | (18.53M) | (21.34M) |
| EPS | 4.95 | 1.80 | -0.72 | -1.60 | -1.54 | -2.19 | -1.40 | -1.50 | -1.30 | -1.49 | -1.71 |
| Free Cash Flow | 78.48M | 91.12M | 1.02M | 2.47M | (24.79M) | (55.50M) | (35.59M) | (18.94M) | (16.20M) | (18.25M) | (22.60M) |
| FCF / Share | 2.67 | 3.06 | 0.03 | 0.09 | -0.91 | -2.13 | -1.49 | -1.30 | -1.20 | -1.46 | -1.81 |
| Operating CF | 116.98M | 130.25M | 24.65M | 11.57M | (20.12M) | (53.05M) | (32.85M) | (18.69M) | (15.79M) | (17.95M) | (22.25M) |
| Total Assets | 907.32M | 808.38M | 676.81M | 564.88M | 295.08M | 281.19M | 181.25M | 200.08M | 25.09M | 13.12M | N/A |
| Total Debt | 32.16M | 31.79M | 24.85M | 16.41M | 34.09M | 30.63M | 25.35M | 24.93M | 16.46M | 15.69M | N/A |
| Cash & Equiv | 104.81M | 150.15M | 185.54M | 441.59M | 214.47M | 190.52M | 22.86M | 97.29M | 8.96M | 6.68M | N/A |
| Book Value | 781.16M | 689.70M | 572.51M | 496.01M | 229.05M | 229.75M | 139.84M | 164.00M | 1.48M | (6.61M) | N/A |
| Return on Equity | 0.19 | 0.08 | -0.04 | -0.09 | -0.18 | -0.25 | -0.24 | -0.13 | -11.80 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 200.58M | 204.58M | 269.08M | 224.50M | 217.09M | 201.32M | 239.72M | 203.19M | 195.88M | 164.01M | 192.51M | 153.30M |
| Net Income | 314,000 | (11.29M) | 136.09M | 9.93M | (3.59M) | 2.99M | 35.22M | 18.50M | 9.79M | (10.01M) | 14.76M | (8.54M) |
| EPS | 0.01 | -0.39 | 4.70 | 0.34 | -0.12 | 0.10 | 1.18 | 0.62 | 0.33 | -0.34 | 0.50 | -0.29 |
| Free Cash Flow | 14.07M | 3.12M | 41.81M | 58.09M | (6.31M) | (15.11M) | 62.15M | 44.28M | (12.47M) | (2.84M) | 9.23M | (3.35M) |
| FCF / Share | 0.49 | 0.11 | 1.44 | 1.98 | -0.21 | -0.51 | 2.08 | 1.48 | -0.42 | -0.10 | 0.31 | -0.11 |
| Operating CF | 23.23M | 12.85M | 52.47M | 68.53M | 2.68M | (6.70M) | 69.18M | 52.28M | (78,000) | 8.86M | 17.27M | 3.64M |
| Total Assets | 925.99M | 911.38M | 918.49M | 807.72M | 802.19M | 730.81M | 808.38M | 796.19M | 728.39M | 685.84M | 676.81M | 639.49M |
| Total Debt | 29.09M | 29.55M | 62.15M | 32.58M | 33.06M | 33.52M | 31.79M | 25.33M | 24.51M | 24.50M | 24.85M | 25.17M |
| Cash & Equiv | 127.76M | 98.93M | 104.81M | 112.84M | 106.93M | 53.88M | 150.15M | 147.51M | 188.03M | 175.42M | 185.54M | 329.90M |
| Book Value | 825.58M | 792.34M | 781.16M | 666.46M | 677.81M | 635.74M | 689.70M | 696.56M | 638.07M | 589.02M | 572.51M | 544.18M |
| Return on Equity | 0.00 | -0.01 | 0.17 | 0.01 | -0.01 | 0.00 | 0.05 | 0.03 | 0.02 | -0.02 | 0.03 | -0.02 |
INSP News
Inspire Medical Systems Inc (INSP) Stock Up 3.3% and Still Undervalued -- GF Score: 64/100
Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC
Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026
Inspire Medical Gains New CPT Codes for Hypoglossal Nerve Stimulation
Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel
Here's Why You Should Retain INSP Stock in Your Portfolio for Now
Is It Too Late to Buy Inspire Medical Systems Inc (INSP) After 5.5% Rally? GF Value Says Undervalued
Hsbc Holdings PLC Has $274,000 Stock Holdings in Inspire Medical Systems, Inc. $INSP
Zacks Industry Outlook Medical Systems, American Well and Butterfly Network
3 Medical Info Systems Stocks to Gain From GenAI Boom Amid Cyber Risk